

Table 2

Correlation Statistics for Cardiopulmonary Bypass and Clamp Times With Variables of Antioxidant Defense and Lipid Peroxidation (Pearson Correlation Coefficient [R] and Statistical Significance [P])

	CPB Time	Clamp Time
<i>GST_p1</i>		
R	−0.398*	−0.389*
P	.036	.041
<i>GST_p2</i>		
R	0.048	0.011
P	.808	.955
<i>GST_p3</i>		
R	−0.464*	−0.427*
P	.013	.023
<i>GSSG_p1</i>		
R	0.287	0.130
P	.138	.510
<i>GSSG_p2</i>		
R	−0.079	0.001
P	.688	.995
<i>GSSG_p3</i>		
R	−0.071	−0.011
P	.720	.955
<i>MDA_p1</i>		
R	−0.218	−0.114
P	.265	.565
<i>MDA_p2</i>		
R	0.000	−0.037
P	1.000	.852
<i>MDA_p3</i>		
R	−0.159	−0.104
P	.418	.599

CPB, cardiopulmonary bypass; GSSG, oxidized glutathione; GST, total glutathione; MDA, malondialdehyde.

* Correlation is significant with $P < .05$ (2-tail test).

given that knowledge to date has been derived from animal models. Such information may have important therapeutic implications, because preventing this phenomenon would afford

greater myocardial protection and improve postoperative outcome.

Raquel Gil-Gómez,^a Javier Blasco-Alonso,^{b,c,*}
Rafael Castillo Martín,^d José Antonio González-Correa,^e
José Pedro de la Cruz-Cortés,^e and Guillermo Milano-Manso^{a,c}

^aUGC Cuidados Críticos y Urgencias Pediátricas, Hospital Regional Universitario de Málaga, Málaga, Spain

^bSección de Gastroenterología y Nutrición Infantil, UGC de Pediatría, Hospital Regional Universitario de Málaga, Málaga, Spain

^cGrupo IBIMA de Investigación Multidisciplinar Pediátrico, Universidad de Málaga, Málaga, Spain

^dSección de Cirugía Cardiovascular Pediátrica, Hospital Regional Universitario de Málaga, Málaga, Spain

^eGrupo LIAIT, Departamento de Farmacología, Facultad de Medicina, Universidad de Málaga, Málaga, Spain

* Corresponding author:

E-mail address: javierblascoalonso@yahoo.es (J. Blasco-Alonso).

Available online 28 January 2015

REFERENCES

1. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. *Hypertension*. 2007;49:241–8.
2. Niccoli G, Celestini A, Calviere C, Cosentino N, Falcioni E, Carnevale R, et al. Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion. *Eur Heart J Acute Cardiovasc Care*. 2013;2:379–88.
3. Van Boven WJ, Gerritsen WB, Driessen AH, Morshuis WJ, Waanders FG, Haas FJ, et al. Myocardial oxidative stress, and cell injury comparing three different techniques for coronary artery bypass grafting. *Eur J Cardiothorac Surg*. 2008;34:969–75.
4. Kotzampassi K, Kolios G, Manousou P, Kazamias P, Paramythiotis D, Papavramidis TS, et al. Oxidative stress due to anesthesia and surgical trauma: importance of early enteral nutrition. *Mol Nutr Food Res*. 2009;53:770–9.
5. Turón Viñas A, Riverola de Veciana A, Moreno Hernando J, Bartrons J, Prada Martínez F, Mayol J, et al. Características y evolución de la transposición de grandes vasos en el periodo neonatal. *Rev Esp Cardiol*. 2014;67:114–9.
6. Tsai MC, Chen WJ, Ching CH, Chuang JI. Resuscitation with hydroxyethyl starch solution prevents nuclear factor kappaB activation and oxidative stress after hemorrhagic shock and resuscitation in rats. *Shock*. 2007;27:527–33.

<http://dx.doi.org/10.1016/j.rec.2014.09.027>

Ventricular Restoration: New Therapeutic Approaches



Restauración ventricular: nuevos enfoques terapéuticos

To the Editor,

Ischemic heart disease is the leading cause of heart failure (HF).¹ Ventricular aneurysms are more common in persons with a prior myocardial infarction, resulting in progressive ventricular remodeling and HF.¹

Our aim is to describe 2 new techniques for ventricular restoration using the Parachute[®] percutaneous device (CardioKinetix; Menlo Park, United States) and the PliCath HF[®] epicardial device (BioVentrix; San Ramon, United States) in patients with HF

and a previous ventricular aneurysm secondary to extensive myocardial infarction. We also discuss the clinical outcomes of 4 patients treated with this new technology.

The Parachute[®] percutaneous device (Figure A) has a self-expanding nitinol structure with anchor-shaped filaments at its distal end, which allow apposition to the ventricular wall and anchoring in the endomyocardium. The metal structure is covered by an impermeable polytetrafluoroethylene membrane, enabling occlusion of the aneurysm cavity, excluding the ventricular aneurysm.^{2,3} A large gauge introducer (16 Fr) is inserted via an arteriofemoral access point, facilitating advancement of the device's delivery system. For the retrograde arterial approach, the left ventricular apex is reached via the aortic valve. Once optimal positioning is achieved, the release and apposition of the device against the ventricular wall is completed by inflating a balloon.

The PliCath HF® epicardial device (Figure B) is implanted using median sternotomy and fluoroscopic guidance. The right ventricle is accessed by inserting a specially-designed curved needle through the anterior ventricular wall and crossing the left ventricular cavity and the septum. To insert this needle, a guide composed of a high-strength biocompatible material (polyetheretherketone) is advanced to the pulmonary artery, and is then used to insert a catheter. A fastening anchor is introduced through this catheter and is then retracted until it comes into contact with the right ventricular face of the septum. The catheter is then removed and another fixing anchor is placed on the outer face of the ventricular wall via the point of needle insertion. Several pairs of anchors are implanted in a similar way until optimal plication of the ventricular aneurysm is achieved. The anchors are composed of a highly resistant material (titanium) and are coated with polyester to facilitate endothelialization.

The 4 patients had extensive anterior myocardial infarction and signs and symptoms of HF. All underwent imaging tests, showing ventricular aneurysms and lack of viability in the left anterior ventricular wall. The first 2 were successfully treated using the Parachute® device, and the others using the PliCath® device. The baseline characteristics of the procedure and follow-up are summarized in the Table.

The anteroapical region is particularly vulnerable to swelling due to its greater curvature and thinner structure. Expansion and thinning of this region, as in the case of ventricular aneurysm following extensive myocardial infarction, increases the ventricular radius and thus wall tension. This eventually degenerates into inefficient ventricular contractility and finally HF.^{3,4}

Classical surgical ventricular restoration procedures using ventricular aneurysm resection were developed to reduce volume and obtain an elliptical ventricular shape, thus halting progressive ventricular remodeling. However, these procedures had a high complications rate related to cannulation, cardiopulmonary bypass, and left ventriculotomy. They were therefore abandoned in routine clinical practice because of their high surgical risk.⁴

New approaches have recently emerged for ventricular restoration, which are less invasive and provide the benefits of restoration therapy without exposing the patient to the greater risk of classical surgical techniques.

The PARACHUTE IV study^{2,3} (NCT00573560, United States and NCT01286116, Europe) evaluated the Parachute® device. Thirty-nine patients with ventricular aneurysms, HF (functional class II-IV), and left ventricular ejection fraction between 15% and 40% were recruited in the US and Europe. The procedure was attempted in 34 patients and was successful in 31. In patients who were successfully treated, diastolic volume was significantly reduced, and 85% of them showed improved functional class. Of the 31 patients, 2 (6.5%) died of cardiac causes in the first 6 months, and no other cardiac deaths occurred during the 3-year follow-up.

CONFIGURE-HF (NCT01568138) is a safety study that is evaluating the PliCath HF® device. This is a multicenter, multinational safety study in patients with previous ventricular aneurysms, ventricular dilation (indexed telesystolic volume ≥ 60 mL / m²) and a left ventricular ejection fraction of 15% to 40%. The primary objective of this study is to assess the overall rate of serious adverse events related to the device.

These initial studies will report the feasibility and safety of these new techniques. We are still at an early stage in the development of this technology, but if further clinical trials confirm that if these techniques are safe and able to halt ventricular remodeling, they may be a therapeutic alternative for these patients.

Table
Baseline Characteristics of the Intervention and Follow-up

Case	Device	Sex	Age, years	Intervention specialists	Anesthesia	Access	Admission, days	Admission complications	LVEDV pre, mL	LVEDV post, mL	LVEF pre, %	LVEF post, %	FC pre	FC post	Follow-up, months
1	Parachute®	Male	64	Interventional cardiologist, cardiac surgeon, anesthesiologist	Sedation + local anesthesia	Femoral surgical dissection	4	No	136	124	25	32	III	II	15
2	Parachute®	Male	67	Interventional cardiologist, cardiac surgeon, anesthesiologist	Sedation + local anesthesia	Femoral surgical dissection	3	No	126	124	30	30	III	I	12
3	PliCath HF®	Male	53	Cardiac surgeon, anesthesiologist	General anesthesia	Medial sternotomy	10	Light post-operative bleeding	103	84	40	48	III	I	6
4	PliCath HF®	Male	49	Cardiac surgeon, anesthesiologist	General anesthesia	Medial sternotomy	13	No	99	101	38	38	III	I	6

FC, New York Heart Association functional class; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume.




Figure. Diagram of the Parachute® and PliCath HF® devices. PTFE, expanded polytetrafluoroethylene.

Diego Fernández-Rodríguez, Ander Regueiro, Salvatore Brugaletta, Omar Gómez-Monteros, José Luis Pomar, and Manel Sabaté*

Servicios de Cardiología y Cirugía Cardiovascular, Hospital Clínic, Barcelona, Spain

* Corresponding author:.

E-mail address: masabate@clinic.ub.es (M. Sabaté).

Available online 2 February 2015

REFERENCES

1. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration

diagnosis and treatment of acute and chronic heart failure 2012. *Eur Heart J.* 2012;33:1787–847.

2. Costa MA, Pencina M, Nikolic S, Engels T, Templin B, Abraham WT. The PARACHUTE IV trial design and rationale: percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure and dilated left ventricles. *Am Heart J.* 2013;165:531–6.

3. Costa MA, Mazzaferri EL, Sievert H, Abraham WT. Percutaneous ventricular restoration using the Parachute® device in patients with ischemic heart failure: Three-year outcomes of the PARACHUTE First-in-Human study. *Circ Heart Fail.* 2014 Jul 18. pii: CIRCHEARTFAILURE.114.001127.

4. Batista RJV, Verde J, Nery P, Bocchino L, Takeshita N, Bhayana JN, et al. Partial left ventriculectomy to treat end-stage heart disease. *Ann Thorac Surg.* 1997;64:634–8.

<http://dx.doi.org/10.1016/j.rec.2014.10.012>

Percutaneous Mitral Valve Repair With Mitraclip® System in a Patient With Acute Mitral Regurgitation After Myocardial Infarction



Reparación valvular mitral con dispositivo MitraClip® en paciente con insuficiencia mitral aguda tras infarto de miocardio

To the Editor,

We present the case of a 76-year-old male patient who was seen at our center for anginal chest pain that had started

24 hours earlier. The electrocardiogram at admission showed pathological inferolateral Q-waves with ST segment elevation in the inferolateral leads. An emergency coronary angiography was performed, which showed occlusion of the proximal circumflex artery and insignificant abnormalities in the other arteries (Figures 1A and B). In this situation, we decided to treat the artery that was causing the infarction, implanting a Multilink 8 3/23 mm stent (Abbott Vascular; Santa Clara, California, United States), with optimal angiographic result (Figure 1C). In the following 24 hours the patient suffered two episodes of acute pulmonary edema, which were controlled with diuretic and